Search 33,000+ CME courses
Back

Haymarket Medical Education

  • Antibodies
  • Autoantibodies
  • Complement System Proteins
  • Edrophonium
  • Myasthenia Gravis

Integrating FcRn and Complement System Therapies for Generalized Myasthenia Gravis

This enduring webcast addresses the autoimmune pathogenesis of gMG and the integration of targeted immune-mediated therapies. The activity will focus on: Autoimmune pathogenesis of gMG – Autoimmune pathology in gMG disease subtypes is governed by divergent mechanisms of immunopathology Anti-AChR autoantibodies – ~85% of gMG cases Anti-MuSK autoantibodies 5-10% of gMG cases Anti-LRP4 antibodies Anti-agrin autoantibodies Seronegative gMG Etiology and Classification – gMG occurs in genetically susceptible individuals, and precipitating factors include infections, immunization, surgeries, and drugs. Early-onset gMG: Age at onset less than 50 years with thymic hyperplasia Late-onset gMG: Age at onset greater than 50 years with thymic atrophy Thymoma-associated gMG The gMG with anti-MuSK antibodies Ocular gMG: Symptoms only from periocular muscles The gMG with no detectable AChR and MuSK antibodies Pathophysiology – The pathophysiologic mechanisms in gMG depend on the type of antibodies present. Nicotinic acetylcholine receptors (n-AChR) gMG Muscle-specific kinase (MuSK) gMG Lipoprotein-related protein 4 (LPR4) gMG Clinical classification of gMG The Myasthenia Gravis Foundation of America (MGFA) clinical classification divides gMG into 5 main classes based on the clinical features and the disease severity. Evaluation – The diagnosis of gMG is primarily clinical. Laboratory investigations and procedures usually aid clinicians in confirming clinical findings. Serologic Tests Electrophysiologic Tests Repetitive nerve stimulation (RNS) test Single-fiber electromyography (SFEMG) test Edrophonium (Tensilon) test Ice-pack test Imaging: Chest computed tomography (CT) or magnetic resonance imaging (MRI) Treatment/Management of gMG Symptomatic treatment Immunosuppressive treatment Intravenous immunoglobulins (IVIG)/plasmapheresis Thymectomy Target-specific Therapies FDA-approved treatments for gMG include: FcRn Inhibitors – Efgartigimod, Rozanolixizumab Complement System Inhibitors – Eculizumab, Zilucoplan, and Ravulizumab Ongoing clinical trials Nipocalimab The mAb targeting FcRn Batoclimab The mAb targeting FcRn

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Credit types

AMA PRA Category 1 Credit™Up to 1.25 creditsNursingUp to 1.25 credits

MOC types

No MOC

FDA REMS

No

Qualifies for MIPS

No

Target Specialties

Pricing

Free

Reported to ACCME by the provider

  • On-demand / recorded video
  • Credit · Up to 1.25 credits
  • Commercial Support
  • Released
    Apr 1, 2026
  • Last day to claim credit
    Apr 2, 2027 6 months left

Related courses

See all

Other providers’ courses on the same topic

More from Haymarket Medical Education

See all

This provider’s courses closest to this one